# PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

Study · id `cardio:ct-nct04971720` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04971720](<https://clinicaltrials.gov/study/NCT04971720>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04971720

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 160 participants.

## Technical summary

Registry record NCT04971720. Randomized; quadruple masking; primary purpose other. Start 2022-02-18 (actual); primary completion 2027-01-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose other
- Phase: Phase 2/3
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT04971720, source copy `cardio:ctgov-nct04971720-2026-04-09`, retrieved 2026-10-26)
- Started: 2022-02-18 (actual) (ClinicalTrials.gov record NCT04971720, source copy `cardio:ctgov-nct04971720-2026-04-09`, retrieved 2026-10-26)
- Primary completion: 2027-01-01 (anticipated) (ClinicalTrials.gov record NCT04971720, source copy `cardio:ctgov-nct04971720-2026-04-09`, retrieved 2026-10-26)
- Completion: 2027-01-01 (anticipated) (ClinicalTrials.gov record NCT04971720, source copy `cardio:ctgov-nct04971720-2026-04-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04971720, source copy `cardio:ctgov-nct04971720-2026-04-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04971720-2026-04-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
- Acronym: PRECISION-BP
- Condition: Obesity
- Condition: Cardiovascular Diseases
- Condition: Hypertension
- Condition: Nocturnal Blood Pressure
- Condition: Natriuretic Peptides
- Condition: Renin-Angiotensin-Aldosterone System
- Intervention (Drug): Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet
- Intervention (Drug): Valsartan 80 mg Oral Tablet
- Lead sponsor: University of Alabama at Birmingham
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: University of Alabama at Birmingham (`cardio:org-university-of-alabama-at-birmingham`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: 8399c0dd92d4f8d3c43c3cf3f9667c0f2b5171f2bf09415554eb825d48231b96
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
